Starting and resulting testosterone levels after androgen supplementation determine at all ages in vitro fertilization (IVF) pregnancy rates in women with diminished ovarian reserve (DOR)

Journal of Assisted Reproduction and Genetics

Volumn 30, Issue 1, 2013, Pages 49-62

  Gleicher, Norbert ^a,b,d   Kim, Ann ^a   Weghofer, Andrea ^a,c   Shohat Tal, Aya ^a   Lazzaroni, Emanuela ^a   Lee, Ho Joon ^a   Barad, David H ^a,b  

^a CENTER FOR HUMAN REPRODUCTION   (United States)

^b Foundation for Reproductive Medicine   (United States)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d CHR   (United States)

Author keywords

Adrenal insufficiency; Androgen deficiency; Androgen supplementation; Androgens; Anti M llerian hormone (AMH); Dehydroepiandrosterone (DHEA); Diminished ovarian reserve; FMR1 gene; Follicle stimulating hormone (FSH); In vitro fertilization (IVF); Pregnancy rates; Premature ovarian aging; Testosterone

Indexed keywords

FOLLITROPIN; FRAGILE X MENTAL RETARDATION PROTEIN; MUELLERIAN INHIBITING FACTOR; PRASTERONE; PRASTERONE SULFATE; TESTOSTERONE;

ADULT; ANDROGEN BLOOD LEVEL; ANDROGEN DEFICIENCY; ARTICLE; COHORT ANALYSIS; CONCEPTION; DIMINISHED OVARIAN RESERVE; DISEASE ASSOCIATION; ENDOMETRIOSIS; FEMALE; FEMALE FERTILITY; FERTILIZATION IN VITRO; GENOTYPE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OVARIAN RESERVE; OVARY FOLLICLE MATURATION; PATHOPHYSIOLOGY; PREDICTOR VARIABLE; PREGNANCY RATE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME; UTERUS DISEASE;

ADULT; AGE FACTORS; ANDROGENS; ANTI-MULLERIAN HORMONE; DEHYDROEPIANDROSTERONE; FEMALE; FERTILIZATION IN VITRO; FOLLICLE STIMULATING HORMONE; FRAGILE X MENTAL RETARDATION PROTEIN; GENOTYPE; HUMANS; INFERTILITY, FEMALE; LOGISTIC MODELS; MENSTRUAL CYCLE; MIDDLE AGED; OVARY; OVULATION INDUCTION; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY RATE; PROSPECTIVE STUDIES; TESTOSTERONE; TREATMENT OUTCOME;

EID: 84873059377     PISSN: 10580468     EISSN: 15737330     Source Type: Journal    
DOI: 10.1007/s10815-012-9890-z     Document Type: Article

References (29)

1. Gleicher N, Weghofer A, Barad DH. The role of androgens in follicle maturation and ovulation induction: friend or foe of infertility treatment? Reprod Biol Endocrinol. 2011;9:116.
2. Sen A, Hammes SR. Granulosa-cell specific androgen receptors are critical regulators of ovarian development and function. Mol Endorcinol. 2010;24:1393-403.
3. Barad DH, Gleicher N. Increased oocyte production after treatment with dehydroepiandrosterone. Fertil Steril. 2005;84(756):e1-3.
4. Mahajan DK. Polycystic ovarian disease: animal models. Endocrinol Metab Clin North Am. 1988;17:705-32.
5. Luchetti CG, Solano ME, Sander V, Arcos ML, Gonzales C, et al. Effects of dehydroepiandrosterone on ovarian cystogenesis and immune function. J Reprod Immunol. 2004;64:59-74.
6. Gleicher N, Barad DH. Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve. Reprod Biol Endocrinol. 2011;9:67.
7. Buster JE, Casson PR, Straughn AB, Dale D, Umstot ES, et al. Postmenopausal steroid replacement with micronized dehydroepiandrosterone: preliminary oral bioavailability and dose proportionality studies Am J Obstet Gynecol. 1992;66:1163-8.
8. Barad DH, Brill H, Gleicher N. Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function. J Assist Reprod Genet. 2007;24:629-34.
9. Weghofer A, Kim A, Barad DH, Gleicher N. (2012) The impact of androgens on pregnancy potential in women with diminished ovarian reserve. Hum Reprod. In press.
10. Eldar-Geva T, Margalioth EJ, Gal M, Ben-Chetrit A, Algur N, et al. Serum anti-Mullerian hormone levels during controlled ovarian stimulation in women with polycystic ovaries with and without hyperandrogenism. Hum Reprod. 2005;20:1814-9.
11. Kristensen SL, Ramlau-Bansen CH, Anderson CY, Ernst E, Olsen SF, et al. The association between circulating levels of antimüllerian hormone and follicle number, androgens, and menstrual cycle characteristics in young women. Fertil Steril. 2012;97:779-85.
12. Frattarelli JL, Peterson EH. Effect of androgen levels on in vitro fertilization cycles. Fertil Steril. 2004;81:1713-4.
13. Frattarelli JL, Gerber MD. Basal and cycle androgen levels correlate with in vitro stimulation parameters but do not predict pregnancy outcome. Fertil Steril. 2006;86:51-7.
14. Gleicher N, Weghofer A, Barad DH. Ovarian reserve determinations suggest new function of FMR1 (fragile X gene) in regulating ovarian aging. Reprod Biomed Online. 2010;20:768-75.
15. Gleicher N, Weghofer A, Lee IH, Barad DH. FMR1 genotype with autoimmunity-Associated polycystic ovary-like phenotype and decreased pregnancy chance. PLoS One. 2010;5:e15303.
16. Gleicher N, Weghofer A, Lee I, Barad DH. Association of FMR1 genotypes with in vitro fertilization (IVF) outcomes based on ethnicity/race. PLoS One. 2011;6:e18781.
17. Barad DH, Weghofer A, Gleicher N. Age-specific levels of basal follicle-stimulating hormone assessment of ovarian function. Obstet Gynecol. 2007;109:1404-10.
18. Barad DH, Weghofer A, Gleicher N. Utility of age-specific serum anti-Müllerian hormone concentrations. Reprod Biomed Online. 2011;22:284-91.
19. Gleicher N, Weghofer A, Barad DH. Defining ovarian reserve to better understand ovarian aging. Reprod Biol Endocrinol. 2011;9:23.
20. Lennie S, Smitz J. Functional Ar signaling is evident in an in vitro mouse follicle culture bioassay that encompasses most stages of folliculogenesis. Biol Reprod. 2009;80:685-95.
21. Gleicher N, Weghofer A, Barad DH. Improvement in diminished ovarian reserve after dehydroepiandrosterone supplementation. Reprod Biomed Online. 2010;21:360-5.
22. Sánchez F, Adriaenssens T, Romero S, Smitz J. Different follicle-stimulating hormone exposure regimens during antral follicle growth alter gene expression in the cumulus-oocyte complex in mice. Biol Reprod. 2010;83:514-24.
23. Gleicher N, Kim A, Weghofer A, Barad DH. Towards a better understanding of functional ovarian reserve: AMH (AMHo) and FSH (FSHo) hormone ratios per retrieved oocyte. J Clin Endocrinol Metabol. 2012;97:995-1004.
24. Gleicher N, Weghofer A, Barad DH. Anti-Müllerian hormone (AMH) defines, independent of age, low versus good live-birth chances in women with severely diminished ovarian reserve. Fertil Steril. 2010;94:2824-7.
25. Gleicher N, Kim A, Weghofer A, Barad DH. (2012) Differences in ovarian aging patterns between races are likely related to ovarian genotypes and sub-genotypes of the FMR1 gene. Reprod Biol Endocrinol. 2012; In press.
26. Yakin K, Urman B. DHEA as a miracle drug in the treatment of poor responders; hype or hope? Hum Reprod. 2011;26:1941-4.
27. Sunkara SK, Coomarasamy A, Arit W, Bhattacharya S. Should androgen supplementation be used for poor ovarian response in IVF? Hum Reprod. 2012;27:637-40.
28. Wiser A, Gonen O, Ghetler Y, Shavit T, Berkovitz A, et al. Addition of dehydroepiandrosterone (DHEA) for poor responder patients before and during IVF treatment improves the pregnancy rate: a randomized prospective study. Hum Reprod. 2010;25:2496-500.
29. Gleicher N, Weghofer A, Kim A, Barad DH. Comparison of ovarian FMR1 genotypes and sub-genotypes in oocyte donors and infertile women. J Assist Reprod Genet. 2012;29:529-32.